IL-8andVEGFR-2polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

2016 ◽  
Vol 17 (1) ◽  
pp. 35-9 ◽  
Author(s):  
Stefano Lazzeri ◽  
Paola Orlandi ◽  
Paolo Piaggi ◽  
Maria Sole Sartini ◽  
Giamberto Casini ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

VEGF-Apolymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

2013 ◽  
Vol 14 (6) ◽  
pp. 623-630 ◽  
Author(s):  
Stefano Lazzeri ◽  
Michele Figus ◽  
Paola Orlandi ◽  
Anna Fioravanti ◽  
Teresa Di Desidero ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Functional Response ◽  
Age Related Macular Degeneration ◽  
Short Term ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Long term intravitreal ranibizumab treatment for exsudative age-related macular degeneration

2013 ◽  
Vol 154 (45) ◽  
pp. 1790-1797 ◽  
Author(s):  
Regina Lukács ◽  
Miklós Resch ◽  
András Papp ◽  
Antal Szabó ◽  
Ágnes Borbándy ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Central Retinal Thickness ◽  
First Year ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Pro Re Nata ◽  
Ranibizumab Treatment

Introduction: The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time. Aim: To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment. Method: 46 patients (age: 75±9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed. Results: The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875). Conclusions: Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently. Orv. Hetil., 154(45), 1790–1797.

scholarly journals CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration

2014 ◽  
Vol 41 (6) ◽  
pp. 386-392 ◽  
Author(s):  
Carlos Eduardo Veloso ◽  
Luciana Negrão Frota de Almeida ◽  
Márcio Bittar Nehemy
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Paired Comparisons ◽  
Nucleotide Polymorphism ◽  
Intravitreal Ranibizumab ◽  
Single Nucleotide ◽  
Age Related ◽  
Y402h Polymorphism

Objective: To investigate the association between CFH gene polymorphism and response to ranibizumab in Brazilian patients with neovascular age-related macular degeneration (AMD).Methods: 95 patients were genotyped for the CFH rs1061170 (Y402H) single nucleotide polymorphism. Patients with neovascular AMD initially received intravitreal ranibizumab injections for three months and were retreated as needed. Visual acuity (VA) and central retinal thickness (CRT) were measured before treatment and at 1, 3, 6, and 12 months post-treatment.Results: For patients with the TT and TC genotypes, paired comparisons of VA showed a statistically significant improvement when the data obtained at all visits were compared with baseline. Patients homozygous for the risk genotype (CC) did not show a statistically significant improvement when VA obtained at visits 1, 3, 6 and 12 were compared with baseline. For all genotypes, paired comparisons of CRT showed a statistically significant improvement when the data obtained at visits 1, 3, 6 and 12 were compared with baseline.Conclusion: Patients with the CC genotype showed poorer long-term functional response to intravitreal ranibizumab.

Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration

2019 ◽  
Vol 257 (7) ◽  
pp. 1459-1466 ◽  
Author(s):  
Alicia Valverde-Megías ◽  
Aurora Ruiz-Calvo ◽  
Antonio Murciano-Cespedosa ◽  
Samuel Hernández-Ruiz ◽  
Jose María Martínez-de-la-Casa ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Nerve Fiber ◽  
Retinal Nerve Fiber Layer ◽  
Term Effect ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Fiber Layer ◽  
Age Related ◽  
Long Term Effect
Sign in / Sign up

Export Citation Format

Share Document